We have learned in the past that trials must have a clear therapeutic endpoint during NIV.^[2] It must be confirmed objectively that this endpoint is achieved, and this should be a demonstration of a reduction in the CO₂ level overnight. It is necessary to significantly reduce elevated PaCO₂ levels once you start HMV in COPD patients, and this criterion is merely true for trials of HMV in COPD.